Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05)
Brief Summary: Multiple myeloma is a malignant incurable hematological disease where survival has been significantly improved by high-dose melphalan with autologous stem cell support (ASCT) in younger patients. However, the disease will eventually relapse and new treatment is demanded. Bortezomib is a newly approved drug for treating relapsing multiple myeloma. It has a different biological effect and response even in patients refractory to conventional chemotherapy. The purpose of the study is in a randomized design to investigate if addition of bortezomib by 20 injections during a 4 months period starting 3 month after ASCT can prolong the time to progression compared to patients receiving no consolidation or maintenance therapy.


Options:
A: Arm Label: VTD; Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Arm Label: TD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): VTD | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): TD, VTD | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell (PBSC) collection; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: First Autologous Transplantation; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Second Autologous Transplantation; Assigned to Arm(s): TD, VTD
B: Arm Label: Velcade-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Dexamethasone | Arm Label: Velcade-Thalidomide-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Thalidomide-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Dexamethasone; Assigned to Arm(s): Velcade-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Thalidomide-Dexamethasone; Assigned to Arm(s): Velcade-Thalidomide-Dexamethasone
C: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR
D: Arm Label: No treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: bortezomib | Arm Label: Bortezomib consolidation; Type: EXPERIMENTAL; Interventions: Drug: bortezomib | Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): Bortezomib consolidation, No treatment

Answer: D